Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306383 | 0.84 | SCN9A (0.54) | SCN9A | |
| SCHEMBL3343014 | 0.83 | SCN9A (0.51) | SCN9AALDH1A1 | |
| SCHEMBL2431152 | 0.75 | SCN9A (0.44) | SCN9AALDH1A1 | |
| SCHEMBL2435768 | 0.73 | SCN9A (0.46) | SCN9A | |
| SCHEMBL3343061 | 0.70 | SCN9A (0.40) | SCN9ACYP2C9 | |
| SCHEMBL2589992 | 0.69 | SCN9A (0.64) | SCN9ACYP2C9ALDH1A1 | |
| SCHEMBL3601475 | 0.66 | SCN9A (0.64) | SCN9A | |
| SCHEMBL3604394 | 0.66 | SCN9A (0.72) | SCN9A | |
| SCHEMBL2585350 | 0.65 | SCN9A (0.47) | SCN9A | |
| SCHEMBL2579638 | 0.65 | SCN9A (0.72) | SCN9ACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| WO-2008046046-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | SCN9A 57/4885CYP2C9 483/4885GPR55 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.